These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 37657032)
1. Analysis of genomic alterations in primary central nervous system lymphoma. He X; Fan X; Shan Y; Ji X; Su L; Wang Y Medicine (Baltimore); 2023 Sep; 102(35):e34931. PubMed ID: 37657032 [TBL] [Abstract][Full Text] [Related]
2. Characterization of genomic alterations in primary central nervous system lymphomas. Zorofchian S; El-Achi H; Yan Y; Esquenazi Y; Ballester LY J Neurooncol; 2018 Dec; 140(3):509-517. PubMed ID: 30171453 [TBL] [Abstract][Full Text] [Related]
3. Analysis of Genomic Alteration in Primary Central Nervous System Lymphoma and the Expression of Some Related Genes. Zhou Y; Liu W; Xu Z; Zhu H; Xiao D; Su W; Zeng R; Feng Y; Duan Y; Zhou J; Zhong M Neoplasia; 2018 Oct; 20(10):1059-1069. PubMed ID: 30227305 [TBL] [Abstract][Full Text] [Related]
4. Whole-Exome Sequencing Revealed the Mutational Profiles of Primary Central Nervous System Lymphoma. Zhang R; Wei B; Hu Y; Lv W; Adilai A; Yang F; Zhang J; Cheng G Clin Lymphoma Myeloma Leuk; 2023 Apr; 23(4):291-302. PubMed ID: 36725383 [TBL] [Abstract][Full Text] [Related]
5. Comparative Molecular Analysis of Primary Central Nervous System Lymphomas and Matched Vitreoretinal Lymphomas by Vitreous Liquid Biopsy. Balikov DA; Hu K; Liu CJ; Betz BL; Chinnaiyan AM; Devisetty LV; Venneti S; Tomlins SA; Cani AK; Rao RC Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576156 [TBL] [Abstract][Full Text] [Related]
6. Diversity of genetic alterations of primary central nervous system lymphoma in Hispanic versus non-Hispanic patients. Barakat M; Albitar M; Whitney R; Abdulhaq H Cancer Treat Res Commun; 2021; 27():100310. PubMed ID: 33581493 [TBL] [Abstract][Full Text] [Related]
7. Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas. Braggio E; Van Wier S; Ojha J; McPhail E; Asmann YW; Egan J; da Silva JA; Schiff D; Lopes MB; Decker PA; Valdez R; Tibes R; Eckloff B; Witzig TE; Stewart AK; Fonseca R; O'Neill BP Clin Cancer Res; 2015 Sep; 21(17):3986-94. PubMed ID: 25991819 [TBL] [Abstract][Full Text] [Related]
8. Frequent Gene Mutations and Their Possible Roles in the Pathogenesis, Treatment and Prognosis of Primary Central Nervous System Lymphoma. Jin Q; Jiang H; Han Y; Li C; Zhang L; Zhang Y; Chai Y; Zeng P; Yue L; Wu C World Neurosurg; 2023 Feb; 170():99-106. PubMed ID: 36396049 [TBL] [Abstract][Full Text] [Related]
9. Molecular Subtypes and Genomic Profile of Primary Central Nervous System Lymphoma. Bödör C; Alpár D; Marosvári D; Galik B; Rajnai H; Bátai B; Nagy Á; Kajtár B; Burján A; Deák B; Schneider T; Alizadeh H; Matolcsy A; Brandner S; Storhoff J; Chen N; Liu M; Ghali N; Csala I; Bagó AG; Gyenesei A; Reiniger L J Neuropathol Exp Neurol; 2020 Feb; 79(2):176-183. PubMed ID: 31886867 [TBL] [Abstract][Full Text] [Related]
10. Analysis of Driver Mutational Hot Spots in Blood-Derived Cell-Free DNA of Patients with Primary Central Nervous System Lymphoma Obtained before Intracerebral Biopsy. Montesinos-Rongen M; Brunn A; Tuchscherer A; Borchmann P; Schorb E; Kasenda B; Altmüller J; Illerhaus G; Ruge MI; Maarouf M; Büttner R; Hansmann ML; Hallek M; Prinz M; Siebert R; Deckert M J Mol Diagn; 2020 Oct; 22(10):1300-1307. PubMed ID: 32745612 [TBL] [Abstract][Full Text] [Related]
11. A Hyperactive RelA/p65-Hexokinase 2 Signaling Axis Drives Primary Central Nervous System Lymphoma. Tateishi K; Miyake Y; Kawazu M; Sasaki N; Nakamura T; Sasame J; Yoshii Y; Ueno T; Miyake A; Watanabe J; Matsushita Y; Shiba N; Udaka N; Ohki K; Fink AL; Tummala SS; Natsumeda M; Ikegaya N; Nishi M; Ohtake M; Miyazaki R; Suenaga J; Murata H; Aoki I; Miller JJ; Fujii Y; Ryo A; Yamanaka S; Mano H; Cahill DP; Wakimoto H; Chi AS; Batchelor TT; Nagane M; Ichimura K; Yamamoto T Cancer Res; 2020 Dec; 80(23):5330-5343. PubMed ID: 33067267 [TBL] [Abstract][Full Text] [Related]
12. Next generation sequencing of vitreoretinal lymphomas from small-volume intraocular liquid biopsies: new routes to targeted therapies. Cani AK; Hovelson DH; Demirci H; Johnson MW; Tomlins SA; Rao RC Oncotarget; 2017 Jan; 8(5):7989-7998. PubMed ID: 28002793 [TBL] [Abstract][Full Text] [Related]
13. Mutational analysis of primary central nervous system lymphoma. Bruno A; Boisselier B; Labreche K; Marie Y; Polivka M; Jouvet A; Adam C; Figarella-Branger D; Miquel C; Eimer S; Houillier C; Soussain C; Mokhtari K; Daveau R; Hoang-Xuan K Oncotarget; 2014 Jul; 5(13):5065-75. PubMed ID: 24970810 [TBL] [Abstract][Full Text] [Related]
14. [Whole Exome Sequencing Reveals Gene Mutation Characteristics of Primary Central Nervous System Lymphoma]. Jin QQ; Jiang HY; Han Y; Li CC; Zhang LT; Wu CY Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Jun; 32(3):756-762. PubMed ID: 38926963 [TBL] [Abstract][Full Text] [Related]
15. Clinicopathological analysis and specific discriminating markers of interleukin detection in cerebrospinal fluid with primary central nervous system lymphoma: results from a retrospective study. Li J; Tang X; Luo X; Liu L; Li D; Yang L Ann Hematol; 2023 Aug; 102(8):2153-2163. PubMed ID: 37289220 [TBL] [Abstract][Full Text] [Related]
16. Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas. Nakamura T; Tateishi K; Niwa T; Matsushita Y; Tamura K; Kinoshita M; Tanaka K; Fukushima S; Takami H; Arita H; Kubo A; Shuto T; Ohno M; Miyakita Y; Kocialkowski S; Sasayama T; Hashimoto N; Maehara T; Shibui S; Ushijima T; Kawahara N; Narita Y; Ichimura K Neuropathol Appl Neurobiol; 2016 Apr; 42(3):279-90. PubMed ID: 26111727 [TBL] [Abstract][Full Text] [Related]
17. The outcome of ibrutinib-based regimens in relapsed/refractory central nervous system lymphoma and the potential impact of genomic variants. Wang S; Zhu Y; Qian X; Ding T; Yuan Y; Li Y; Wu H; Chen T Adv Clin Exp Med; 2023 Aug; 32(8):855-863. PubMed ID: 36881367 [TBL] [Abstract][Full Text] [Related]
18. CD79B Y196 mutation is a potent predictive marker for favorable response to R-MPV in primary central nervous system lymphoma. Yamaguchi J; Ohka F; Lushun C; Motomura K; Aoki K; Takeuchi K; Nagata Y; Ito S; Mizutani N; Ohno M; Suzaki N; Takasu S; Seki Y; Kano T; Wakabayashi K; Oyama H; Kurahashi S; Tanahashi K; Hirano M; Shimizu H; Kitano Y; Maeda S; Yamazaki S; Wakabayashi T; Kondo Y; Natsume A; Saito R Cancer Med; 2023 Mar; 12(6):7116-7126. PubMed ID: 36478416 [TBL] [Abstract][Full Text] [Related]
19. Non-invasive detection of somatic mutations using next-generation sequencing in primary central nervous system lymphoma. Fontanilles M; Marguet F; Bohers É; Viailly PJ; Dubois S; Bertrand P; Camus V; Mareschal S; Ruminy P; Maingonnat C; Lepretre S; Veresezan EL; Derrey S; Tilly H; Picquenot JM; Laquerrière A; Jardin F Oncotarget; 2017 Jul; 8(29):48157-48168. PubMed ID: 28636991 [TBL] [Abstract][Full Text] [Related]
20. Whole-Genome/Exome Sequencing Uncovers Mutations and Copy Number Variations in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System. Zhu Q; Wang J; Zhang W; Zhu W; Wu Z; Chen Y; Chen M; Zheng L; Tang J; Zhang S; Wang D; Wang X; Chen G Front Genet; 2022; 13():878618. PubMed ID: 35646048 [No Abstract] [Full Text] [Related] [Next] [New Search]